Right drug in right dose for right patient at right time via right route is defined as one of the promising outcome of personalized, multi-omic medicine. Systematic drug repositioning enables the translation of insights from computational analyses coupled with laboratory based or experimental findings to bench side in a shorter span of time. From the first report of drug repositioning in early 1950s till 2016, more than 250 successful reports have been published in the literature. We analyzed the repertoire of such cases reported and derived a molecular code for drug repositioning. The analyses of the data in the format of drugs, primary indications and secondary indications reveal molecular preferences; ligand classes, functional roles and pathways were drug repositioning was successful. We envisage our first report on global analyses of successful drug repositioning space and RepurposeDB could help to develop predictive models of drug repositioning and can have major influence in personalized drug repositioning, an emerging therapeutic area in data-driven, individualized medicine.
Explore repositioned drug cataloged in RepurposeDB
Primary and secondary indications of drugs cataloged in RepurposeDB
If you have a new indication to existing drug, contribute to RepurposeDB
If you'd like access to the RepurposeDB source data, you can find it here
Our research focuses on the development and use of translational and biomedical informatics approaches to address critical challenges in systems medicine and biomedical informatics. We are interested in identifying and developing novel therapeutic and diagnostic approaches for human disease through integration and analysis of molecular and clinical data, and also perform research to develop and evaluate methods to incorporate genomic sequencing data into clinical practice.
For the academic community the content of RepurposeDB is licensed under CC0 (public domain dedication). Commercial entities interested in licensing the RepurposeDB content, please contact Dr. Joel Dudley.
Design, development and analytics of RepurposeDB is supported by the following National Institutes of Health (NIH) grants:
If you use RepurposeDB or the associated data, please cite us!
Khader Shameer, Benjamin S. Glicksberg, Rachel Hodos, Kipp W. Johnson, Marcus A. Badgeley, Ben Readhead, Max S. Tomlinson, Timothy O’Connor, Riccardo Miotto, Brian A. Kidd, Rong Chen, Avi Ma’ayan, Joel T. Dudley; Systematic analyses of drugs and disease indications in RepurposeDB reveal pharmacological, biological and epidemiological factors influencing drug repositioning. Brief Bioinform 2017 bbw136. doi: 10.1093/bib/bbw136
Please contact us if you have questions or comments about RepurposeDB. You can also contact us if you need help in submitting your drug repositioning investigation to RepurposeDB.